Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.

A small group of slow-growing cells causes basal cell carcinoma to return after treatment.

Baricitinib may effectively treat nail changes in alopecia areata.

KIT's role in skin cells is not entirely independent, as other cells can influence its function.

JAK inhibitors show promise in treating difficult skin diseases.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Tofacitinib treatment is used for teenagers with alopecia areata.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

JAK inhibitors are effective treatments for alopecia areata.